« Return to News | R&D Trends

Mitsubishi Tanabe Pharma acquires Medicago in $357 million deal

Friday, July 12, 2013 03:13 PM

Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Quebec-based Medicago, a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs).

Under the arrangement, MTPC will acquire all of the issued and outstanding common shares of Medicago other than those shares currently held by Philip Morris Investments (PMI), an affiliate of Philip Morris International and MTPC, for $1.16 per share in cash. Medicago will be jointly owned by MTPC (60%) and PMI (40%).

The transaction represents a value of approximately $357 million, including the assumption of Medicago’s existing debt.

Medicago’s board of directors has approved the deal and has recommended shareholders vote in favor of it.

"MTPC’s capabilities in biopharmaceutical research, development and commercialization, along with its financial stability, offer us the ideal opportunity to realize the full potential of our platform,” said Andy Sheldon, president and chief executive officer of Medicago. “These resources provide us the ability to foster the development of innovative vaccines with the financial stability to expand our Quebec, Canadian, U.S. and global operations."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.